The Latest Cardiac and Vascular News
Combination of Hēlo Thrombectomy System and Hēlo Return establish the first 510(k)-cleared platform compatible with continuous vacuum aspiration MENLO PARK, Calif., Oct. 12, 2026 /PRNewswire/ — Endovascular Engineering, Inc. (E2), a commercial-stage medical technology company focused on…
CAUTION: Investigational device. Limited by United States law to investigational use. FLAGSTAFF, Arizona/USA (October 1, 2026)—W. L. Gore & Associates’ medical business (Gore) announced today the first patient enrollment in the IBE Plus Pivotal Study, a clinical trial evaluating the investigational GORE® EXCLUDER® IBE Plus Stent Graft for the treatment […]
ALISO VIEJO, Calif., Oct. 7, 2026 /PRNewswire/ — Okami Medical, a medical technology company developing novel vascular embolization solutions, announced today that the U.S. FDA has granted an expanded indication for its LOBO® Vascular Occlusion System. The expanded indication extends the…
Live case showcases successful below-the-knee revascularization with two MOTIV® scaffolds; late-breaking analysis shows higher efficacy endpoint rates with MOTIV versus balloon angioplasty in both Rutherford 4 and Rutherford 5 CLTI populations SAN DIEGO, Oct. 6, 2026 /PRNewswire/ — REVA…
SAN JOSE, Calif.–(BUSINESS WIRE)–Shape Memory Medical Inc., the developer of proprietary volume-expanding shape memory polymer solutions for endovascular embolization, today announced that Brazil’s national health surveillance agency, ANVISA (Agência Nacional de Vigilância Sanitária), has granted authorization for the IMPEDE Embolization Plug, the IMPEDE-FX Embolization Plug, and the IMPEDE-FX RapidFill. The approval process was supported by Biomedical, which acts as Shape Memory Medical’s Br
MIAMI LAKES, Fla.–(BUSINESS WIRE)– #Cordis–Cordis, a global leader in interventional cardiovascular and endovascular technologies, today announced that the SELUTION SLR SUSTANE™ PTA Drug-Eluting Balloon (SUSTANE DEB) achieved the highest reported 12-month primary patency in the SELUTION4SFA US pivotal trial at 90.3%. The results were presented during a Late-Breaking Clinical Trial session at VIVA 2026 by Jay Mathews, MD, MS, Director, Cardiac Catheterization Laboratory, PERT & Structural Heart at
News comes on heels of recent expanded U.S. payer coverage, reaching 96% of commercially and Medicare insured lives, expanding greater access to care Medtronic, a global leader in healthcare technology, announced new prospective findings from the VenaSeal™ Spectrum Program, further strengthening the evidence supporting the VenaSeal™ closure system across […]
SANTA ROSA, Calif.–(BUSINESS WIRE)–Endologix Holdings, LLC today announced Rhevera Medical as its new corporate brand. The new identity reflects the company’s broader commitment to partnering with physicians who treat complex vascular disease and supporting patients whose lives, mobility and independence depend on the company’s technologies. For decades, Endologix has worked alongside physicians who care for patients with serious vascular conditions, including abdominal aortic aneurysms and p
LAS VEGAS, Oct. 4, 2026 /PRNewswire/ — The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine through education and research, today announced results from the Late-Breaking Clinical Trials presented at The VEINS 2026 conference, held at…
MENLO PARK, Calif.–(BUSINESS WIRE)– #AVENTUSThrombectomy–Inquis Medical, a medical device company pioneering advanced treatments for venous thromboembolic disease, today announced the U.S. commercial launch of the latest AVENTUS™ Catheter, designed to provide physicians with 360° sweeping directional aspiration for clot removal within the vasculature. Austin Bourgeois, MD, performed the first-in-human pulmonary embolism (PE) procedure using the new catheter at Huntsville Hospital in Huntsville, Alabama. AVENTUS is
